Compounded semaglutide, tirzepatide and liraglutide could be harder to come by starting this summer, if the U.S. Food and ...
A majority of GLP-1 lawsuits come from patients who allege that manufacturers have inadequately warned about severe side ...
FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...
There is no shortage of headlines about GLP-1 medications. Originally developed to manage blood sugar levels, these medications are now widely known for promoting weight loss. Alongside their rapid ...